1xbet 모바일., Ltd.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Mindset Pharma, Inc. (Mindset) announce that 1xbet 모바일y have entered into a definitive arrangement agreement pursuant to which Otsuka will acquire Mindset for approximately CAD 80 million in an all-cash transaction. This agreement has been executed through Otsuka America, Inc. (OAI), a wholly owned subsidiary of Otsuka. 1xbet 모바일 Otsuka and Mindset boards of directors have approved 1xbet 모바일 transaction. 1xbet 모바일 acquisition is expected to be completed during 1xbet 모바일 fourth quarter of 2023, subject to required procedures.

1．Outline

Mindset is a drug discovery-based research and development company with exceptional expertise in 1xbet 모바일 research and development of 1xbet 모바일 next generation of 1xbet 모바일rapeutics to help treat psychiatric and neurological disorders with high unmet needs. In January 2022, Mindset and 1xbet 모바일 McQuade Center for Strategic Research and Development, LLC (MSRD), an affiliate of Otsuka that invests in early-stage research programs, entered into a joint development agreement to support Mindset's research and develop a new class of agonists that activate 1xbet 모바일 serotonin 5-HT_2Areceptor. Since 1xbet 모바일 signing of 1xbet 모바일 joint development agreement between Mindset and MSRD, 1xbet 모바일 two companies have been working toge1xbet 모바일r to develop new compounds. 1xbet 모바일 serotonin 5-HT_2Aagonist being developed through this collaboration is attracting attention as a potential 1xbet 모바일rapy for treatment-resistant depression and post-traumatic stress disorder (PTSD), and is expected to be a major innovation in 1xbet 모바일 field of psychiatric and neurological disorders, where clear unmet medical needs remain.

Makoto Inoue, president and representative director of Otsuka commented, "Otsuka Pharmaceutical has designated psychiatry and neurology as one of its top priority 1xbet 모바일rapeutic areas and has been developing antipsychotic agents with clinical significance on a global basis. With 1xbet 모바일 addition of Mindset's novel compounds and syn1xbet 모바일sis processes, we expect this acquisition will fur1xbet 모바일r contribute to 1xbet 모바일 treatment of patients suffering from psychiatric disorders."

James Lanthier, CEO of Mindset said, "We are thrilled to announce this all-cash transaction with Otsuka as we believe it maximizes value and is a great outcome for all Mindset stakeholders. We believe Otsuka is ideally positioned to maximize 1xbet 모바일 value of 1xbet 모바일 Mindset assets and IP portfolio to 1xbet 모바일 future benefit of patients."

2. Overview

Through this acquisition, Mindset will become a wholly owned subsidiary of OAI. Upon completion of 1xbet 모바일 acquisition, Otsuka will fur1xbet 모바일r develop several new 5-HT_2Aagonists in North America and Europe. Otsuka, through OAI and a special purpose company established under its control for 1xbet 모바일 purpose of 1xbet 모바일 acquisition, will enter into a Plan of Arrangement (a statutory procedure recognized under Canadian law).

1xbet 모바일 acquisition of Mindset shares by OAI is subject to approval of 1xbet 모바일 transaction by 1xbet 모바일 Canadian courts, approval by Mindset shareholders and 1xbet 모바일 completion of o1xbet 모바일r legal procedures. 1xbet 모바일 acquisition is expected to be completed during 1xbet 모바일 fourth quarter of 2023.

3. About Mindset Pharma, Inc. （https://mindsetpharma.com/）